These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29492946)

  • 1. Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?
    Bourlon MT; Velázquez HE; Luna-Santiago R; Vázquez-Manjarrez S; Bourlon C
    Oncology (Williston Park); 2018 Feb; 32(2):64-8. PubMed ID: 29492946
    [No Abstract]   [Full Text] [Related]  

  • 2. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
    Ullén A
    Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
    [No Abstract]   [Full Text] [Related]  

  • 3. From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis.
    Necchi A; Raggi D; Giannatempo P; Sonpavde G; Galsky MD; Bellmunt J; Mariani L; Miceli R
    Clin Genitourin Cancer; 2017 Oct; 15(5):509-512.e9. PubMed ID: 28478885
    [No Abstract]   [Full Text] [Related]  

  • 4. Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.
    Galsky MD
    Nat Rev Urol; 2018 Feb; 15(2):71-72. PubMed ID: 29182606
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab in urothelial bladder carcinoma.
    Hamilou Z; Lavaud P; Loriot Y
    Future Oncol; 2018 Feb; 14(4):331-341. PubMed ID: 29135284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutics: Spoilt for choice.
    Eisenstein M
    Nature; 2017 Nov; 551(7679):S36-S38. PubMed ID: 29117155
    [No Abstract]   [Full Text] [Related]  

  • 8. B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects.
    Yu L; Wang Y; Shao S; Yang M; Niu H; Yu Q; Wang X
    Tumori; 2015; 101(5):549-54. PubMed ID: 26045125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy in uropathology].
    Verkarre V; Roussel H; Granier C; Tartour E; Allory Y
    Ann Pathol; 2017 Feb; 37(1):90-100. PubMed ID: 28111042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
    Barclay J; Creswell J; León J
    Arch Esp Urol; 2018 May; 71(4):393-399. PubMed ID: 29745928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
    Zichi C; Tucci M; Leone G; Buttigliero C; Vignani F; Pignataro D; Scagliotti GV; Di Maio M
    Biomed Res Int; 2017; 2017():5618174. PubMed ID: 28680882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis.
    Patel J; Crawford JM
    Biochemistry; 2018 Feb; 57(6):901-903. PubMed ID: 29350031
    [No Abstract]   [Full Text] [Related]  

  • 14. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.
    Gill DM; Sonpavde G; Pal SK; Agarwal N
    Immunotherapy; 2017 May; 9(6):463-466. PubMed ID: 28472906
    [No Abstract]   [Full Text] [Related]  

  • 15. Making urothelial carcinomas less immune to immunotherapy.
    Ramos JD; Yu EY
    Urol Oncol; 2016 Dec; 34(12):534-537. PubMed ID: 27836245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel biomarkers in bladder cancer.
    Cheng ML; Iyer G
    Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-PD-L1 inhibitor durvalumab in bladder cancer.
    Brower V
    Lancet Oncol; 2016 Jul; 17(7):e275. PubMed ID: 27321156
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer immunotherapy: weak beats strong.
    Deppert W; Bruns M
    Aging (Albany NY); 2016 Nov; 8(11):2607-2608. PubMed ID: 27920406
    [No Abstract]   [Full Text] [Related]  

  • 20. Making cancer immunotherapy a surer bet.
    Eisenstein M
    Nature; 2017 Dec; 552(7685):S72-S73. PubMed ID: 29293218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.